TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Average mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerance of multiple oral doses of larazotide acetate
Endpoint domain: Adverse events/effects
Primary endpoint: Quantifiable concentrations of larazotide acetate in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Short Form Health Survey-36 (SF36)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Treatment Baseline in MADRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prehension functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in mean number of nursing interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in trunk flexor endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in trunk extensor endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sit and reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of anesthetic/fluid leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Bone volume obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of catheters malfunctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Biberoglu and Bergham Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in vaginal and gut microbiome and urinary metabolites profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza hemagglutination inhibition (HAI) titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil differential response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient toxicities and their grades
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge of reproduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of lifestyle related factors affecting fertility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Residents Who Received SARS-CoV-2 Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Severity of uremic xerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of FSH from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cardiovascular health improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Modified SOFA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic activity in frontal and temporal lobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of disease inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average percent signal change of activated voxels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Resting Motor Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MAX intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with ≥1 adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) as assessed by blinded independent central review (BICR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Error related negativity amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in photo ratings
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Intention to Use PrEP Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Initiate PrEP by Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Uterine Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Temperature comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom clusters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Function Using the Hip disability and Osteoarthritis Outcome Score Activities of Daily Living Subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Function Using the Hip disability and Osteoarthritis Outcome Score Symptom Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Are Adherent to Treatment Attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relief of obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Preoperative Anxiety Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sick listing - self reported
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in prevalence of Methicillin-sensitive Staphylococcus aureus (MSSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in prevalence of Methicillin-resistant Staphylococcus aureus (MRSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of DCV, ASV and BMS-791325
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of DCV, ASV and BMS-791325
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 28 all causes mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of treatment discontinuation due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of fluid in Douglas pouch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Able to Tolerate an Oral Food Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anatomical changes in brainstem structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: iron deposition in brainstem structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Responsiveness of WDEQ-A-Sp
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Loss of Control Eating Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in optic nerve sheath diameter (ONSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ankle proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability via satisfaction survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Demand (attendance/adherence) of yoga intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting and Postprandial gastric volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline plasma glucagon-like peptide 1 at 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline serum triglycerides at 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline serum glucose at 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline serum Insulin at 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline serum B-hydroxybutyrate at 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in degree of arterial stiffness measured by pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in vascular calcification on CT scans of superficial femoral artery and aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: adherence to first prescription refill after discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of students who are truant
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Objective tumor response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MR (mitral regurgitation) grade after clip treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of doses of analgesic drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Opiate secondary withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of acceptance of alerts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of study-related problems added to problem lists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of care impact based on NCQA's HEDIS measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Knee Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of hospitalization for serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Hematocrit Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of gastric emptying rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Completion of chemotherapy cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of chronic postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with potentially bleeding lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of PET plus CXR at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of motion sickness
Endpoint domain: Adverse events/effects
Primary endpoint: Score on Young Mania Rating Scale (YMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supraspinatus strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effectiveness of iron treatment for iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Child PTSD Symptom Scale (CPSS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician-Administered PTSD Scale for DSM-5, Child/Adolescent Version (CAPS-CA-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Global Scale of Illness - Improvement/Severity (CGI-I/S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Bilirubin (TB) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Phototherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Homocysteine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quantification of endometrial immune cells spatial distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of severe neonatal hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Scapular Muscles Endurance (SME) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IGRA positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IGRA conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Sociocultural Attitudes towards Appearance Questionnaire-4, Affects by Media subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in physical condition (6 minutes walk test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical condition (Borg scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological development at 2 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Study Group Subjects Switched to Standard Arm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of post-transplant response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current forced expiratory volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Eradication of SARS COV-2 from respiratory tract secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Predicted longevity
Endpoint domain: Mortality/survival
Primary endpoint: Change in hydration status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximally tolerated dose (MTD) of AVID200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with response eligibility for Phase 1b
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Wound Epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor-to-background ratio on delayed scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor-to-background ratio on standard scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of antibiotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in coronary spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of post-induction hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fetuin-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alanine transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gamma-glutamyl transferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Complete Remission, Partial Response, or no Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot ulcer surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fasting triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IVC collapsibility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall Severity Score (OSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance (sensitivity, specificity, accuracy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Continuation Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AF Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease persistence or recurrence after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Exhibit Any Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects reporting solicited adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Discrete Incidence of Chronic Kidney Disease Patient Safety Indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with symptom resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of people cohabiting with a patient not developing VRI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation dose exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of SNPs genetic polymorphisms in RORC gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of Test of Memory and Learning (TOMAL) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sedation Success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Frequency of Spasm Clusters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability of CDX-527
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Steady-State Concentration (Css) for Norelgestromin (NGMN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Steady-State Concentration (Css) for Ethinyl Estradiol (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 (Patch Application) to Time 168 hours Post-dose (AUC[0-168]) for NGMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Erythropoietin Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in HIV-1 RNA Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-D kinematic measurements of cervical motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Pen Needle Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain of the hemiplegic shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state AUC0-24 of Glecaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state AUC0-24 of Pibrentasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of intermittent hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: TMS Evoked Potential (TEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of 8-isoprostane, MDA and DNA damage in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Modified Tardieu Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: detection rate of neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: In-stent neointimal volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum Concentration (Cmax) of Venlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC) of Venlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Desvenlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC) of Desvenlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Desvenlafaxine after DVS SR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes